Assoc. Prof. JULIANA HAMZAH, PhD
Inventor/Founder/
Chief Scientific Officer (CSO)
A/Prof. Juliana Hamzah leads groundbreaking research in targeted drug delivery for atherosclerotic cardiovascular disease at Harry Perkins Institute. Backed by major nationally competitive grants and over 20 years of innovation, she has advanced precision therapy, culminating in ATH01, a novel therapeutic targeting atherosclerotic disease, reshaping how we treat arterial blockage at its source. Juliana leads a research team advancing the preclinical trials.
Prof. SHIRLEY JANSEN
MBChB FRACS FRCS PhD
Founder/Executive Director/Chief Medical Officer (CMO)
Prof. Shirley Jansen is a leading vascular surgeon with over 25 years’ experience treating atherosclerotic disease. As Head of Department, Sir Charles Gairdner Hospital and Director of the Heart & Vascular Research Institute , she has led 30+ clinical trials and first-in-human therapies. Her cross-disciplinary research bridges medicine, surgery and bioengineering to revolutionise vascular treatment, outcomes, and innovation in care.
Dr. JAMES WILLIAMS, PhD
Non-Executive Director
Dr. James Williams is a biotech entrepreneur, investor, and commercialisation leader with 25+ years' experience turning medical research into global ventures. He co-founded Dimerix Limited and iCeutica Inc., which have secured over $1 billion in licensing deals and three FDA drug approvals, respectively. Now CEO of the Health Translation Group, he draws on deep expertise in commercialisation and venture capital to support new ventures based on Western Australian research discoveries.
